The first coronavirus vaccine tested on humans appears safe and generated antibodies which stopped the virus replicating, according to early trial results shared on Monday.
Eight healthy volunteers saw few adverse effects after taking two doses of the potential vaccine, according to Moderna, its manufacturer based in Massachusetts.
It appeared to trigger an immune response – the critical requirement of a working vaccine – producing “neutralising antibodies” in all eight of the patients.
The levels of those antibodies were similar to that found in people who caught Covid-19 and then recovered.
Dr Tal Zaks, Moderna’s chief medical officer, called the result a “first important step”, with much more testing needed. Some medical experts urged caution, seeking more data.
A second phase of trials with around 600 people will begin soon, while a third involving thousands of people will start in July.
Moderna’s stock price was up 40 per cent in pre-market trading as the results emerged. The positive news is only one step in the long road to a potential vaccine.
Even if the coming trials are successful Moderna’s vaccine would not be available until between January and June 2021.
However, given there is some doubt that a vaccine can even be found, the results provide hope that a breakthrough can be achieved.
US stock markets surged in early trading as the news emerged, with the Dow Jones industrial average initially up 3.5 per cent.
Currently there is no proven treatment or vaccine for Covid-19. Dozens of companies across the world are scrambling to develop a vaccine.